TrialLancet (London, England)2017
Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
Stephen Russell et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1,103 papers cite itlatest 60 shown
this paperpooled ittrialcites it